Merck's investment narrative in the biotech market seems to be shifting following the FDA's approval of the subcutaneous KEYTRUDA QLEX. The stock of Merck has surged, spearheaded by innovative game-changing oncology drugs. Trump's proposed tariffs on pharma could potentially raise the stocks of Eli Lilly, Merck, and Pfizer. An increase in Merck shares has been realized by multiple companies such as First American Bank, 1834 Investment Advisors Co., Howard Capital Management Group LLC, American National Bank & Trust, ARS Wealth Advisors Group LLC, Assenagon Asset Management S.A. among others, while others such as Signaturefd LLC, Randolph Co Inc, State of Alaska Department of Revenue and Eagle Global Advisors LLC have reduced their stock holdings in the company. Kai Beckmann's appointment as CEO of Merck KGaA has led to a downturn in the company's stocks. Nevertheless, the stock still appears undervalued with an excellent dividend yield, and Merck's consistent dividends display its resilience in the market amidst uncertainties. Verona Pharma shareholders have approved a $10 billion acquisition by Merck, paving a path with a potential 40% upside for Merck's stock.
Merck Stocks News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 27 Sep 2025 21:30:51 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor -5
